DifGen Pharmaceuticals LLC (DifGen) has acquired Aveva Drug Delivery Services Inc., a fully integrated developer and manufacturer of transdermal delivery systems (TDS) and oral dissolvable films (ODF).

In a statement, Ramandeep Singh Jaj, Founder and Co-CEO of DifGen said: “The acquisition of Aveva Drug Delivery Services, with its 300 plus employees, marks an important milestone for DifGen as it adds its first pharmaceutical manufacturing base in the U.S. This strategic investment allows us to expand our R&D and manufacturing capabilities in offering complex dosage forms and secure supply to our valuable partners with local US based manufacturing.”

Santhanakrishnan Srinivasan, Founder and Co-CEO of DifGen said: “We are excited to bring Aveva DDS as an integral part of the DifGen family. With its world class development and manufacturing infrastructure and top of the line scientific talent, the Aveva DDS acquisition expands our R&D infrastructure to include a highly capital intensive and complex drug-device combination Transdermal Drug delivery systems and thin film-based products, areas that complement our existing infrastructure but also require specialized formulation and processing capabilities as well as specialized equipment.”

Srinivasan noted that these formulations comprise single or multi-layered designs exhibiting a complex set of performance attributes, including uniquely controlled delivery profiles, adhesion, physical characteristics, and a variety of analytical testing requirements. “TDS follows a complex set of regulatory and clinical requirements, and device design requirement that the scientific and operations team at Aveva DDS is adept at,” said Srinivasan.